Blueshift Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Blueshift Asset Management LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 339 shares of the biopharmaceutical company’s stock, valued at approximately $356,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. International Assets Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after acquiring an additional 96,266 shares during the period. TD Asset Management Inc lifted its holdings in Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after acquiring an additional 82,034 shares during the period. Icon Wealth Advisors LLC boosted its position in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Regeneron Pharmaceuticals by 86.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 144,865 shares of the biopharmaceutical company’s stock worth $152,257,000 after purchasing an additional 67,235 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on REGN. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Evercore ISI lowered their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Trading Up 0.2 %

Shares of REGN stock opened at $754.87 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The stock has a market cap of $82.95 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.91 and a beta of 0.15. The company’s 50-day moving average price is $913.54 and its 200-day moving average price is $1,020.69. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.